医学
脉络膜
巩膜
眼压
眼科
青光眼
透明质酸
失明
房水
自愈水凝胶
超声生物显微镜
外科
视网膜
验光服务
化学
有机化学
物理
光学
解剖
作者
Huijie Hao,Binbin He,Y. Bai,Jianhai Yang,Xiaoli Xing,Wenguang Liu
出处
期刊:Biomaterials advances
日期:2022-11-01
卷期号:142: 213162-213162
被引量:4
标识
DOI:10.1016/j.bioadv.2022.213162
摘要
Glaucoma is the primary cause of irreversible blindness worldwide. The current treatments are primarily based on drug usage or surgical operation to reduce intraocular pressure (IOP). However, it is expensive and requires patients to insist on taking the medicine for a long time. The suprachoroidal space (SCS) is the space between the choroid and the sclera, which forms part of the uveovortex pathway in the circulation of aqueous humor. So far, it is still challenging to realize the injection of hydrogels into the SCS with long-term duration. In this work, an in situ-forming polyzwitterionic polycarboxybetaine hydrogel is designed and injected to expand SCS to increase the drainage of aqueous humor from the eye via the uveovortex pathway, thus reducing IOP for at least 6 weeks, while commercial hyaluronic acid hydrogel can only last for about 4 weeks. The clinical ophthalmological safety assessment examination shows that the treatment of polyzwitterion hydrogel is well-tolerated that leads to minimal inflammatory reaction, and histopathology assessment demonstrates that the SCS is expanded after injection of the hydrogel. Further analysis of ultrasound biomicroscopy reveals that there is a strong correlation between IOP reduction and SCS expansion. In short, the polyzwitterion hydrogel developed in this work can prolong the period of IOP reduction by expanding SCS, thus treating ocular hypertension and glaucoma without resorting to drugs or regular surgery.
科研通智能强力驱动
Strongly Powered by AbleSci AI